Belite Bio, Inc (BLTE)

NASDAQ: BLTE · Real-Time Price · USD
80.23
-2.22 (-2.69%)
Nov 22, 2024, 4:00 PM EST - Market closed
-2.69%
Market Cap 2.48B
Revenue (ttm) n/a
Net Income (ttm) -33.03M
Shares Out 30.88M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 72,803
Open 82.00
Previous Close 82.45
Day's Range 78.00 - 82.00
52-Week Range 31.01 - 86.53
Beta -1.60
Analysts Strong Buy
Price Target 89.00 (+10.93%)
Earnings Date Nov 12, 2024

About BLTE

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy tha... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 20
Stock Exchange NASDAQ
Ticker Symbol BLTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price forecast is $89.0, which is an increase of 10.93% from the latest price.

Price Target
$89.0
(10.93% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Belite Bio, Inc. (NASDAQ:BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer...

10 days ago - Seeking Alpha

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative ...

17 days ago - GlobeNewsWire

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel ther...

19 days ago - GlobeNewsWire

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel the...

2 months ago - GlobeNewsWire

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Belite Bio, Inc (NASDAQ:BLTE) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Ha...

3 months ago - Seeking Alpha

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeu...

3 months ago - GlobeNewsWire

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...

3 months ago - GlobeNewsWire

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative ...

3 months ago - GlobeNewsWire

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel ther...

5 months ago - GlobeNewsWire

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

Belite Bio, Inc. (NASDAQ:BLTE) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-...

6 months ago - Seeking Alpha

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative ...

6 months ago - GlobeNewsWire

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeut...

6 months ago - GlobeNewsWire

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative ...

6 months ago - GlobeNewsWire

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative r...

7 months ago - GlobeNewsWire

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease in a...

7 months ago - GlobeNewsWire

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) --  Belite Bio, Inc. (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel the...

7 months ago - GlobeNewsWire

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel thera...

7 months ago - GlobeNewsWire

Belite Bio Announces $25 Million Registered Direct Offering

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel the...

7 months ago - GlobeNewsWire

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

SAN DIEGO, March 22, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel the...

8 months ago - GlobeNewsWire

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...

9 months ago - GlobeNewsWire

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel the...

9 months ago - GlobeNewsWire

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...

9 months ago - GlobeNewsWire

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerativ...

9 months ago - GlobeNewsWire

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...

10 months ago - GlobeNewsWire